Although details of the trial and the efficacy of the drug treatment are still unknown, the study is still good news for the potential it may bring to scientists’ further understanding of anti-Mag and other forms of autoimmune neuropathy.
Researchers at Indiana University School of Medicine have developed a prototype for a blood test that can objectively measure pain. The objective measure of pain can lead to better diagnoses and better treatments.
The Foundation for Peripheral Neuropathy hosted a webinar on the affect that new tax regulations may have on charitable giving, in the U.S. and how donors can continue to contribute to meaningful causes in tax-friendly ways. Speakers included Lou Mazawey, President of the Foundation for Peripheral Neuropathy and Principal, Groom Law, Mark Friese, Senior Vice President-Wealth Management for Menick, Friese, Phillips Bock Group/Merrill Lynch &Co, and Daniel H. Ruttenberg, Attorney and Counsellor at Law, SmolenPlevy.
Mark Friese has provided additional information on charitable planned giving and some planned giving structures that allow you to make an impact with your gift and receive potential tax benefits as well. You can find this information here.
Please contact Lindsay at [email protected] or 847-883-9942 if you have any questions for FPN or for our expert webinar panel.
The Foundation for Peripheral Neuropathy provides education and support today as we walk toward a cure for tomorrow.
Support us in advancing a cure!
FPN is a non-profit organization that is solely funded by our readers.